Bleeding complication with liver biopsy: Is it predictable?

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 10, 2010, Pages 826-829

  Caldwell, Stephen ^a   Northup, Patrick G ^a  

^a UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PROTEIN C;

EDITORIAL; HEMATOTHORAX; HEMOBILIA; HEMOPERITONEUM; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HEMATOMA; LIVER HEMORRHAGE; LOW DRUG DOSE; PROTEIN C DEFICIENCY; SUBCAPSULAR HEMATOMA;

ANGIOGRAPHY; ARTERIES; BIOPSY, NEEDLE; FEMALE; HEMORRHAGE; HISTOCYTOCHEMISTRY; HUMANS; LIVER DISEASES; MALE; MICROSCOPY; MIDDLE AGED; RADIOGRAPHY, ABDOMINAL; RISK FACTORS; THROMBOCYTOPENIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77957162503     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2010.06.010     Document Type: Editorial

References (23)

1. Seeff L.B., Everson G.T., Morgan T.R., et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C Trial. Clin Gastroenterol Hepatol 2010, 8:877-883. HALT-C TRIAL GROUP.
2. Rockey D.C., Caldwell S.H., Goodman Z.D., et al. Liver biopsy. Hepatology 2009, 49:1017-1044.
3. Malloy P.C., Grassi C.J., Kundu S., et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol 2009, 20:S240-S249.
4. Tripodi A., Chantarangkul V., Primignani M., et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007, 46:520-527.
5. Bellest L., Eschwege V., Poupon R., et al. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 2007, 46:528-534.
6. Lisman T., van Leeuwen Y., Adelmeijer J., et al. Interlaboratory variability in assessment of the model of end-stage liver disease score. Liver Int 2008, 28:1344-1351.
7. Trotter J.F., Brimhall B., Arjal R., et al. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004, 10:995-1000.
8. Trotter J.F., Olson J., Lefkowitz J., et al. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transplant 2007, 7:1624-1628.
9. Porte R.J., Lisman T., Tripodi A., et al. The International Normalized Ratio (INR) in the MELD score: problems and solutions. Am J Transplant 2010, 10:1349-1353.
10. Tripodi A., Primignani M., Chantarangkul V., et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009, 137:2105-2111.
11. Lisman T., Bongers T.N., Adelmeijer J., et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006, 44:53-61.
12. Northup P.G., McMahon M.M., Ruhl A.P., et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006, 101:1524-1528. quiz 1680.
13. Sogaard K.K., Horvath-Puho E., Gronbaek H., et al. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009, 104:96-101.
14. Ferguson J.W., Helmy A., Ludlam C., et al. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency. Thromb Res 2008, 121:675-680.
15. Gunawan B., Runyon B. The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Aliment Pharmacol Ther 2006, 23:115-120.
16. Smalberg J.H., Leebeek F.W. Superimposed coagulopathic conditions in cirrhosis: infection and endogenous heparinoids, renal failure, and endothelial dysfunction. Clin Liver Dis 2009, 13:33-42.
17. Cunningham M.T., Brandt J.T., Laposata M., et al. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med 2002, 126:499-505.
18. Tripodi A., Primignani M., Chantarangkul V., et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006, 44:440-445.
19. Sharma P., McDonald G.B., Banaji M. The risk of bleeding after percutaneous liver biopsy: relation to platelet count. J Clin Gastroenterol 1982, 4:451-453.
20. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981, 26:388-393.
21. Lindor K.D., Bru C., Jorgensen R.A., et al. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 1996, 23:1079-1083.
22. Manolakopoulos S., Triantos C., Bethanis S., et al. Ultrasound-guided liver biopsy in real life: comparison of same-day prebiopsy versus real-time ultrasound approach. J Gastroenterol Hepatol 2007, 22:1490-1493.
23. Stone M.A., Mayberry J.F. An audit of ultrasound guided liver biopsies: a need for evidence-based practice. Hepatogastroenterology 1996, 43:432-434.